News & Updates

Show Multimedia Only

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026 by

Treatment with the short-acting glycoprotein IIb/IIIa inhibitor tirofiban after intravenous thrombolysis (IVT) results in significant improvements in 90-day functional outcomes among patients with acute ischaemic stroke, with no increase in haemorrhage or mortality, a study has shown.

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026

Statin may be more harmful than beneficial in people with dementia

14 Feb 2026

For individuals with dementia, statin use does not appear to provide cardioprotective benefits but rather contributes to an increased risk of hospitalization due to cardiovascular or cerebrovascular events, according to a retrospective study.

Statin may be more harmful than beneficial in people with dementia

14 Feb 2026

Vitamin D, calcium supplementation does little to improve bone mass in teens

13 Feb 2026 by

For adolescents with perinatally acquired HIV, supplementation with vitamin D3 and calcium appears to have limited benefit in terms of promoting bone accrual and mineralization, as shown in the phase III VITALITY study.

Vitamin D, calcium supplementation does little to improve bone mass in teens

13 Feb 2026

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026 by

Treatment with mirikizumab results in significant improvements in clinical, endoscopic, and histologic outcomes during induction and maintenance phases in patients with Crohn’s disease (CD) or ulcerative colitis (UC), according to an updated meta-analysis of randomized controlled trials (RCTs).

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026 by

Treatment with either vedolizumab or ustekinumab delivers significant and meaningful benefits to patients with Crohn’s disease (CD), but each has its distinct therapeutic profile with complementary advantages, reports a real-world study presented at CCC 2026.

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

13 Feb 2026

Peppermint oil or peppermint sweets appear to do little in terms of relieving pain in children with irritable bowel syndrome (IBS) or functional abdominal pain–not otherwise specified, as shown in a study.

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

13 Feb 2026

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026 by

The use of intra-arterial (IA) alteplase following a successful endovascular thrombectomy (EVT) improves 90-day functional outcome in patients with large-vessel occlusion (LVO) acute ischaemic stroke compared with EVT-alone, according to the CHOICE 2* trial presented at ISC 2026.

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

12 Feb 2026 by

Three months of romosozumab followed by 9 months of denosumab works just as well as 12 months of romosozumab for increasing bone mass in postmenopausal women at high risk of fracture, as shown in an open-label, noninferiority trial.

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

12 Feb 2026

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026 by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026

Prophylactic marstacimab fares well in haemophilia A or B without inhibitors

11 Feb 2026 by

Results of the BASIS trial demonstrate the efficacy and safety of once-weekly SC marstacimab prophylaxis up to 12 months in male adolescents and adults with severe haemophilia A* (HA) or severe-to-moderately-severe haemophilia B** (HB) with no detectable or documented history of inhibitors against factors VIII or IX, and who were receiving on-demand (OD) or routine prophylaxis (RP) prior to enrolment.

Prophylactic marstacimab fares well in haemophilia A or B without inhibitors

11 Feb 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Adjunct tirofiban improves functional outcomes in AIS

Adjunct tirofiban improves functional outcomes in AIS

Statin may be more harmful than beneficial in people with dementia

Statin may be more harmful than beneficial in people with dementia

Vitamin D, calcium supplementation does little to improve bone mass in teens

Vitamin D, calcium supplementation does little to improve bone mass in teens

Mirikizumab improves IBD outcomes during induction, maintenance periods

Mirikizumab improves IBD outcomes during induction, maintenance periods

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Prophylactic marstacimab fares well in haemophilia A or B without inhibitors

Prophylactic marstacimab fares well in haemophilia A or B without inhibitors